News

Number of news items returned: 181 to 200 records of 397

Appee Ltd Announcement

04 March 2016

(10863 views)

"Appee Ltd has drawn international attention by signing its first USA customer - Automobile Club of Southern California (a member ...

50% month-on-month revenue growth, expanding team and China

29 February 2016

(11884 views)

"Squirel Ltd (“Squirel” or the “Company”) is pleased to announce the appointment of Fiona Hong a senior financial services professional ...

Australian Trading & Investment Corporation Ltd Announcement

23 February 2016

(12912 views)

"... Foundation ready for growth New Sales Manager appointed   ...Additional expenditure has been focused on expansion. We have secured premises in the CBD ...

Appee new 2016!

19 February 2016

(11664 views)

"2015 was a year of firsts for appee. From our first beta release of the appee product and website, to ...

Ocular Robotics Appoints US Based Leading Global Supplier of Autonomy Components as Distribution Partner

18 February 2016

(11237 views)

"AutonomouStuff the leading supplier of components to the rapidly growing autonomy sector has been appointed as an Ocular Robotics distributor ...

BioCube commissions machine in Congo for Palm Oil conversion to Biodiesel

30 January 2016

(11828 views)

"The BioCube Corporation (BC) has successfully commissioned a BioCube 250 for Feronia Inc at its Yaligimba Palm Oil plantation in the ...

2016 So Far, Not So Good

29 January 2016

(11707 views)

"... Whilst 2015 may have finished with a Santa rally in capital markets, 2016 has started horribly with losses across the ...

Gartner lists Opmantek in 2016 Market Guide for Network Automation

27 January 2016

(12415 views)

"Opmantek (ASSOB:OMK) a multi award winning provider of IT infrastructure management and Audit solutions, today announced that it has been ...

Australian Trading & Investment Corporation Ltd – Update

21 January 2016

(11297 views)

"To all interested parties, welcome to an exciting 2016! ...Since our last update we’re finding tremendous traction in setting the foundation ...

Equity Crowdfunding and Investment Opportunties

29 December 2015

(11818 views)

Looking to assist investors and private businesses in 2016 - from the team at Funding Strategies.   Funding Strategies provides Corporate ...

2015: An Inflection Point?

16 December 2015

(11839 views)

"As 2015 draws to a close the year we thought we’d recap the year and look at what’s on the ...

CRe8 Home & Finance Ltd – last chance to participate in this innovative company

14 December 2015

(11807 views)

"...CRe8 has had a stellar 2015, the highlights of which are listed below; Glenvill Homes (CRe8’s home builder partner) committed to ...

Opmantek Sales growth a new record

14 December 2015

(11645 views)

"Opmantek (ASSOB:OMK) has continued on its high growth trajectory signing significant customer agreements in November throughout the USA and Latin ...

Ocular Robotics RE05 3D Scanner to be used in European Space Agency Moon Exploration Project, Rovina Project Shows Off Digital Reconstruction of the ARIS Priscilla Catacombs

08 December 2015

(12185 views)

"Ocular Robotics RE05 3D Scanner to be used in European Space Agency Moon Exploration Project.   Aerospace company GMV have been awarded ...

Australian Trading and Investment Corporation Investor Update

07 December 2015

(11743 views)

"To all interested parties, Since our last update there have been some exciting updates, as listed below:   ..Our model portfolio increased by ...

BioCube Corporation: A Promising Year End for BioCube

04 December 2015

(12130 views)

"This has been a busy and exciting few weeks for the team at BioCube Corporation. Commencing with an Austrade mission ...

BioCube Raising $3 Million

13 November 2015

(12165 views)

The Eco Investor website published the following article about BioCube on November 13th, 2015:   "The developer of a portable and community-sized ...

Funding Strategies Connect - November 2015

12 November 2015

(11642 views)

Dear Readers, Today it is my pleasure to introduce you to BioCube, Appee and China Dairy. Ocular Robotics and Opmantek have both ...

Pre-Christmas Networking Event Invitation

11 November 2015

(10913 views)

We are delighted to invite you  to a pre-Christmas networking event over drinks and canapes with the Funding Strategies &  ...

CRe8 Home & Finance: Close of offer – 18th December 2015

10 November 2015

(11561 views)

To Whom It May Concern: CRe8 has received a positive response from its offer with the following highlights:   Round 1 closed within ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625